Viyash Scientific completes acquisition of BioForLife Italia
- Viyash Scientific's subsidiary Alivira Animal Health acquired 100% of BioForLife Italia S.r.l.
- Base purchase consideration paid on closing is EUR 15.0 million
- Deferred consideration of EUR 1.976 million payable subject to adjustments
- Acquisition completed on October 1, 2026, making BFL Italy a step-down subsidiary
*this image is generated using AI for illustrative purposes only.
Viyash Scientific Limited announced the completion of its step-down subsidiary's acquisition of 100% share capital in BioForLife Italia S.r.l. on October 1, 2026. The transaction expands the company's animal health footprint in Europe through its Irish subsidiary, Alivira Animal Health Limited.
Alivira Animal Health Limited, a wholly owned subsidiary of Viyash, executed the deal pursuant to a Sale and Purchase Agreement dated July 21, 2026. Consequently, BioForLife Italia S.r.l., based in Milan, Italy, has become a step-down wholly owned subsidiary of Viyash Scientific with effect from October 1, 2026.
Transaction Consideration Structure
The financial terms of the acquisition involve a split payment structure comprising an upfront base consideration and a deferred component. The total value is contingent on the net financial position of the target entity as calculated at specific intervals.
| Component | Amount (EUR) | Status |
|---|---|---|
| Base purchase consideration | 15.0 million | Paid on closing |
| Deferred consideration | 1.976 million | Payable post-adjustments |
The deferred portion is subject to necessary adjustments based on the computation of the net financial position as on the Closing Date, October 1, 2026, in accordance with the SPA terms.
Regulatory and Operational Updates
This completion follows earlier disclosures made by the company on June 8, 2026, July 21, 2026, and September 8, 2026. The transaction was intimated to BSE and NSE under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
As part of the closing procedures under the SPA, representatives from Alivira Animal Health Limited have been appointed to the Board of Directors of BioForLife Italia S.r.l. The company stated that the transaction stands consummated and closed in accordance with all previously disclosed terms and conditions.
Historical Stock Returns for Viyash Scientific
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.72% | -8.67% | -13.33% | +26.76% | +24.40% | +5.46% |
How will the integration of BioForLife Italia's product portfolio impact Viyash Scientific's revenue mix in the European animal health segment over the next fiscal year?
What specific operational synergies or cost-saving measures is management targeting through the new board representation at BioForLife Italia?
How might the deferred consideration adjustments based on the net financial position affect Viyash's short-term cash flow projections for FY2027?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
